AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review

AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

AstraZeneca Plc Key Recent Developments

Aug 08,2024: Conduit acquires three first-in-class assets from AstraZeneca
Jul 25,2024: AstraZeneca Releases Half-Year Report
Jul 01,2024: Aptamer Group Signs New Agreement With AstraZeneca
May 31,2024: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
AstraZeneca Plc - Key Facts
AstraZeneca Plc - Key Employees
AstraZeneca Plc - Key Employee Biographies
AstraZeneca Plc - Major Products and Services
AstraZeneca Plc - History
AstraZeneca Plc - Company Statement
AstraZeneca Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
AstraZeneca Plc - Business Description
Other Break-up: Alliance Revenue
Performance
Other Break-up: Collaboration Revenue
Overview
Performance
Other Break-up: Product Sales
Overview
Performance
Geographical Segment: Australia
Performance
Geographical Segment: Canada
Performance
Geographical Segment: China
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Italy
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Others
Performance
Geographical Segment: Spain
Performance
Geographical Segment: Sweden
Performance
Geographical Segment: UK
Performance
Geographical Segment: US
Performance
R&D Overview
AstraZeneca Plc - Corporate Strategy
AstraZeneca Plc - SWOT Analysis
SWOT Analysis - Overview
AstraZeneca Plc - Strengths
AstraZeneca Plc - Weaknesses
AstraZeneca Plc - Opportunities
AstraZeneca Plc - Threats
AstraZeneca Plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
AstraZeneca Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 08, 2024: Conduit acquires three first-in-class assets from AstraZeneca
Jul 25, 2024: AstraZeneca Releases Half-Year Report
Jul 01, 2024: Aptamer Group Signs New Agreement With AstraZeneca
May 31, 2024: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
May 23, 2024: Astrazeneca Demonstrates Commitment to Patients Living With Amyloidosis at the 2024 International Symposium on Amyloidosis
May 22, 2024: Astrazeneca Furthers Ambition To Transform Outcomes in Early Lung Cancer and Redefine Metastatic Breast Cancer Treatment at ASCO 2024
May 21, 2024: Astrazeneca Sets Ambition To Deliver $80 Billion Total Revenue by 2030 And Sustained Growth Post 2030
May 20, 2024: AstraZeneca to build $1.5bn ADCs facility in Singapore
May 15, 2024: BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected
May 02, 2024: AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
AstraZeneca Plc, Key Facts
AstraZeneca Plc, Key Employees
AstraZeneca Plc, Key Employee Biographies
AstraZeneca Plc, Major Products and Services
AstraZeneca Plc, History
AstraZeneca Plc, Subsidiaries
AstraZeneca Plc, Joint Venture
AstraZeneca Plc, Key Competitors
AstraZeneca Plc, Ratios based on current share price
AstraZeneca Plc, Annual Ratios
AstraZeneca Plc, Annual Ratios (Cont...1)
AstraZeneca Plc, Annual Ratios (Cont...2)
AstraZeneca Plc, Interim Ratios
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
AstraZeneca Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
AstraZeneca Plc, Performance Chart (2019 - 2023)
AstraZeneca Plc, Ratio Charts
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings